ZNTL
Zentalis Pharmaceuticals, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
-19/100
Last price
2.68
▼ 0.10 (3.60%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.90
Prev close
2.78
Day high
2.82
Day low
2.65
Volume
827.56K
Market cap
$261.99M
P/E (TTM)
—
52W range
1.21 – 6.95
Day trading desk
Gap from prior close
+4.32%
Prior close 2.78
VWAP
2.71
-1.20% from price
Relative volume
0.64×
Normal
Session range
25.59%
2.54 – 3.19
Position in range
22%
Near session low
ATR (14D)
0.19
7.10% of price
Prior day high
2.84
PDH
Prior day low
2.63
PDL
Bid / ask spread
—
Quote not published
Session volume
770.19K
Avg 1.21M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.66%
-3.6%
1M
-33.08%
-34.2%
3M
-45.06%
-49.6%
6M
0.00%
-18.2%
YTD
+97.78%
+83.5%
1Y
+65.84%
+49.4%
3Y
-86.69%
-168.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ZNTL open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
15.66M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 30, 26 | BRUNS INGMAR Officer |
STOCK | 9.73K | $26.94K | Direct |
| Aug 14, 26 | WALTERS GROUP Beneficial Owner of more than 10% of a Class of Security |
BUY | 4.33M | $15.17M | Indirect |
| Jun 16, 26 | MYERS SCOTT DUNSETH Director |
STOCK | 57.10K | $0 | Direct |
| Jun 16, 26 | WALKER LUKE NATHANIEL Director |
STOCK | 57.10K | $0 | Direct |
| Jun 16, 26 | JOHNSON DAVID MICHAEL Director |
STOCK | 57.10K | $0 | Direct |
| Jun 16, 26 | SKVARKA JAN Director |
STOCK | 57.10K | $0 | Direct |
| Jun 16, 26 | KARIUKI ENOCH Director |
STOCK | 57.10K | $0 | Direct |
| May 26, 26 | CAMPBELL SHANNON Director |
STOCK | 114.20K | $0 | Direct |
| Feb 10, 26 | VULTAGGIO VINCENT Officer |
SELL | 40.22K | $97.56K | Direct |
| Feb 9, 26 | EASTLAND JULIA MARIE Chief Executive Officer |
SELL | 8.76K | $21.24K | Direct |
| Feb 9, 26 | BRUNS INGMAR Officer |
SELL | 3.30K | $8.00K | Direct |
| Feb 3, 26 | VULTAGGIO VINCENT Officer |
SELL | 3.10K | $7.88K | Direct |
| Dec 31, 25 | WALTERS GROUP Beneficial Owner of more than 10% of a Class of Security |
BUY | 6.46M | $7.75M | Indirect |
| Dec 15, 25 | MATRIX CAPITAL MANAGEMENT COMPANY, LP Beneficial Owner of more than 10% of a Class of Security |
SELL | 7.50M | $9.97M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
JOHNSON DAVID MICHAEL |
Director | 307.52K | Stock Award(Grant) |
KARIUKI ENOCH |
Director | 194.47K | Stock Award(Grant) |
LACKNER MARK |
Officer | 512.86K | Stock Award(Grant) |
MATRIX CAPITAL MANAGEMENT COMPANY, LP |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
MYERS SCOTT DUNSETH |
Director | 395.89K | Stock Award(Grant) |
PAUL ANDREA |
Officer | 1.07M | Stock Award(Grant) |
SKVARKA JAN |
Director | 264.25K | Stock Award(Grant) |
VULTAGGIO VINCENT |
Officer | 146.51K | Sale |
WALKER LUKE NATHANIEL |
Director | 201.38K | Stock Award(Grant) |
WALTERS GROUP |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
Fundamentals
Market cap$261.99M
Enterprise value$54.45M
Revenue (TTM)—
Gross profit—
EBITDA$-149.77M
Net income$-139.54M
EPS (TTM)$-1.96
Free cash flow$-79.45M
Total cash$174.61M
Total debt$37.69M
Book value / share$2.00
Shares outstanding98.12M
Float56.64M
Short % of float5.71%
Dividend yield0.00%
Beta (5Y)1.94
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.44
PEG ratio—
Price / sales—
Price / book1.33
EV / revenue—
EV / EBITDA-0.36
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-66.75%
Return on assets-33.15%
Debt / equity26.24
Current ratio4.82
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $67.42M | $0 | $0 | -100.0% |
| Operating revenue | $0 | $67.42M | $0 | $0 | -100.0% |
| Research & development | $107.30M | $167.77M | $189.59M | $172.73M | -36.0% |
| Selling, general & admin | $37.72M | $87.11M | $64.35M | $54.55M | -56.7% |
| Total operating expense | $145.01M | $254.88M | $253.94M | $227.29M | -43.1% |
| Operating income | -$145.01M | -$187.46M | -$253.94M | -$227.29M | +22.6% |
| Pre-tax income | -$136.62M | -$165.69M | -$276.89M | -$221.30M | +17.5% |
| Tax provision | $442.00K | $177.00K | -$601.00K | -$469.00K | +149.7% |
| Net income | -$137.06M | -$165.84M | -$292.19M | -$236.81M | +17.4% |
| Net income to common | -$137.06M | -$165.84M | -$292.19M | -$236.81M | +17.4% |
| Basic EPS | -1.91 | -2.33 | -4.47 | -4.48 | +18.0% |
| Diluted EPS | -1.91 | -2.33 | -4.47 | -4.48 | +18.0% |
| EBIT | -$145.01M | -$187.46M | -$253.94M | -$227.29M | +22.6% |
| EBITDA | -$144.27M | -$186.17M | -$252.55M | -$225.86M | +22.5% |
| Basic shares | 71.87M | 71.08M | 65.41M | 52.86M | +1.1% |
| Diluted shares | 71.87M | 71.08M | 65.41M | 52.86M | +1.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $35.99M | $33.90M | $28.04M | $43.07M | — | +6.2% |
| Cash & short-term investments | $245.89M | $371.08M | $482.92M | $437.37M | — | -33.7% |
| Accounts receivable | — | — | — | — | $4.00K | — |
| Total current assets | $253.19M | $386.07M | $496.72M | $451.93M | — | -34.4% |
| Property, plant & equipment | $29.04M | $37.23M | $41.73M | $50.08M | — | -22.0% |
| Goodwill & intangibles | — | $0 | $3.74M | $3.74M | $3.74M | — |
| Total assets | $288.97M | $430.34M | $551.69M | $539.31M | — | -32.9% |
| Total current liabilities | $36.56M | $52.73M | $69.37M | $56.65M | — | -30.7% |
| Total debt | $35.70M | $39.58M | $43.15M | $45.17M | — | -9.8% |
| Total liabilities | $72.76M | $93.15M | $114.30M | $105.29M | — | -21.9% |
| Retained earnings | -$1.19B | -$1.05B | -$888.56M | -$596.37M | — | -13.0% |
| Shareholder equity | $216.20M | $337.19M | $437.28M | $433.80M | — | -35.9% |
| Working capital | $216.63M | $333.34M | $427.35M | $395.29M | — | -35.0% |
| Net tangible assets | $216.20M | $337.19M | $433.55M | $430.07M | — | -35.9% |
| Shares issued | 69.09M | 71.28M | 70.77M | 59.28M | — | -3.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$137.06M | -$165.87M | -$292.31M | -$237.11M | — | +17.4% |
| Depreciation & amortisation | $739.00K | $1.29M | $1.39M | $1.43M | — | -42.7% |
| Stock-based compensation | $20.72M | $67.27M | $54.82M | $46.84M | — | -69.2% |
| Change in working capital | -$9.12M | -$16.54M | $5.86M | $13.25M | — | +44.8% |
| Operating cash flow | -$125.25M | -$170.86M | -$207.82M | -$163.75M | — | +26.7% |
| Capital expenditure | — | -$221.00K | -$583.00K | -$2.55M | -$6.11M | — |
| Investing cash flow | $131.62M | $176.56M | -$44.46M | -$114.18M | — | -25.5% |
| Share buybacks | -$9.98M | $0 | $0 | — | — | — |
| Financing cash flow | -$4.28M | $108.00K | $237.30M | $261.04M | — | -4,064.8% |
| Free cash flow | -$125.25M | -$171.08M | -$208.41M | -$166.30M | — | +26.8% |
| End cash position | $38.62M | $36.53M | $30.72M | $45.70M | — | +5.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $35.16M | $28.72M | $29.49M | $22.95M | $27.61M | — | +22.5% |
| Selling, general & admin | $9.23M | $9.14M | $7.91M | $10.78M | $8.45M | — | +1.0% |
| Total operating expense | $44.39M | $37.85M | $37.39M | $33.73M | $36.06M | — | +17.3% |
| Operating income | -$44.39M | -$37.85M | -$37.39M | -$33.73M | -$36.06M | — | -17.3% |
| Pre-tax income | -$42.15M | -$35.23M | -$34.77M | -$26.69M | -$26.87M | — | -19.6% |
| Tax provision | $138.00K | $120.00K | $442.00K | $0 | $0 | — | +15.0% |
| Net income | -$42.29M | -$35.35M | -$35.22M | -$26.69M | -$26.87M | — | -19.6% |
| Net income to common | -$42.29M | -$35.35M | -$35.22M | -$26.69M | -$26.87M | — | -19.6% |
| Basic EPS | -0.59 | -0.50 | — | -0.37 | -0.37 | -0.67 | -18.0% |
| Diluted EPS | -0.59 | -0.50 | — | -0.37 | -0.37 | -0.67 | -18.0% |
| EBIT | -$44.39M | -$37.85M | -$37.39M | -$33.73M | -$36.06M | — | -17.3% |
| EBITDA | -$44.24M | -$37.70M | -$37.24M | -$33.57M | -$35.90M | — | -17.3% |
| Basic shares | 71.33M | 70.26M | — | 72.14M | 71.99M | 71.68M | +1.5% |
| Diluted shares | 71.33M | 70.26M | — | 72.14M | 71.99M | 71.68M | +1.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $24.78M | $31.93M | $35.99M | $39.07M | $37.60M | -22.4% |
| Cash & short-term investments | $174.61M | $211.76M | $245.89M | $280.70M | $303.43M | -17.5% |
| Total current assets | $181.28M | $218.10M | $253.19M | $288.30M | $311.60M | -16.9% |
| Property, plant & equipment | $27.30M | $28.25M | $29.04M | $33.12M | $34.26M | -3.4% |
| Total assets | $215.33M | $253.07M | $288.97M | $327.25M | $351.71M | -14.9% |
| Total current liabilities | $37.63M | $35.24M | $36.56M | $37.17M | $39.02M | +6.8% |
| Total debt | $33.56M | $34.65M | $35.70M | $36.71M | $37.69M | -3.2% |
| Total liabilities | $71.68M | $70.39M | $72.76M | $74.38M | $77.21M | +1.8% |
| Retained earnings | -$1.27B | -$1.23B | -$1.19B | -$1.16B | -$1.13B | -3.4% |
| Shareholder equity | $143.65M | $182.68M | $216.20M | $252.87M | $274.50M | -21.4% |
| Working capital | $143.65M | $182.86M | $216.63M | $251.13M | $272.57M | -21.4% |
| Net tangible assets | $143.65M | $182.68M | $216.20M | $252.87M | $274.50M | -21.4% |
| Shares issued | 71.67M | 71.16M | 69.09M | 72.25M | 72.14M | +0.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$42.29M | -$35.35M | -$35.22M | -$26.69M | -$26.87M | -19.6% |
| Depreciation & amortisation | $153.00K | $151.00K | $157.00K | $160.00K | $160.00K | +1.3% |
| Stock-based compensation | $3.21M | $3.20M | $3.12M | $4.83M | $6.29M | +0.6% |
| Change in working capital | $1.73M | -$728.00K | -$1.38M | -$1.17M | -$8.33M | +337.8% |
| Operating cash flow | -$37.24M | -$32.96M | -$30.94M | -$26.96M | -$34.71M | -13.0% |
| Capital expenditure | — | -$34.00K | — | — | — | — |
| Investing cash flow | $30.02M | $30.01M | $32.45M | $28.32M | $30.38M | +0.0% |
| Financing cash flow | $65.00K | -$1.12M | -$4.59M | $115.00K | $0 | +105.8% |
| Free cash flow | -$37.24M | -$32.99M | -$30.94M | -$26.96M | -$34.71M | -12.9% |
| End cash position | $27.41M | $34.56M | $38.62M | $41.70M | $40.23M | -20.7% |
Options analytics
Put / call volume
0.87
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
0.50
-81.3% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+12.5%
Puts bid over calls
Call volume
39
Contracts, this expiry
Put volume
34
Contracts, this expiry
Heaviest call OI
0.50
0 contracts
Heaviest put OI
1.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.48 | -0.59 | -22.9% |
| Mar 2026 | -0.52 | — | — |
| Dec 2025 | -0.61 | -0.49 | +19.9% |
| Sep 2025 | -0.48 | -0.37 | +22.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.55 | 7 | $0 | 0.0% |
| Next quarter | -0.51 | 7 | $0 | 0.0% |
| Current year | -2.02 | 8 | $0 | 0.0% |
| Next year | -1.82 | 8 | $12.81M | 0.0% |
Analyst targets & ownership
Mean target$7.33
High target$10.00
Low target$5.00
Implied upside173.63%
Analyst count9
ConsensusBUY
Strong buy / Buy0 / 6
Hold4
Sell / Strong sell0 / 0
Held by insiders21.85%
Held by institutions50.88%
Institutions holding154
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.70
-0.67% from price
SMA 20
3.00
-10.87% from price
SMA 50
3.69
-27.55% from price
SMA 100
3.92
-31.70% from price
SMA 200
3.43
-22.17% from price
EMA 12
2.80
-4.44% from price
EMA 26
3.11
-13.96% from price
EMA 50
3.46
-22.47% from price
RSI (14)
35.2
Neutral
MACD (12,26,9)
-0.31
Hist 0.01
ATR (14)
0.19
7.13% of price
Realised vol 30D
67.6%
Annualised
Bollinger upper
3.71
20, 2σ
Bollinger lower
2.28
20, 2σ
50 / 200 cross
Golden
3.69 vs 3.43
Trend bias
Below 200
-22.17%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.96
More volatile than market
Correlation to SPY
0.20
Largely independent
Realised vol 30D
67.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-61.9%
Peak to trough
Max drawdown 5Y
-98.8%
Peak to trough
ATR 14
0.19
7.13% of price
Beta (reported)
1.94
5Y monthly, from filing
Short interest
Shares short
4.79M
Prior 5.97M
Change vs prior
-19.9%
Shorts covering
% of float
5.71%
Normal
% of shares out
4.88%
Against total outstanding
Days to cover
5.0
Crowded exit
Float
56.64M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 16, 26 | William Blair | INITIATED | — | Outperform |
| Jul 23, 26 | Rodman & Renshaw | INITIATED | — | Buy |
| Jul 17, 26 | Mizuho | INITIATED | — | Outperform |
| Apr 10, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Mar 27, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Nov 12, 25 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Aug 7, 25 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| May 15, 25 | Wedbush | MAINTAINED | Neutral | Neutral |
| May 15, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 28, 25 | Wedbush | MAINTAINED | Neutral | Neutral |
| Mar 27, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 17, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-18
Corporate Changes & Voting Matters
8-K · 2026-05-27
Corporate Changes & Voting Matters
8-K · 2026-05-21
Corporate Changes & Voting Matters
8-K · 2026-05-12
Corporate Changes & Voting Matters
8-K · 2026-05-05
Proxy Statements
DEF 14A · 2026-04-30
Corporate Changes & Voting Matters
8-K · 2026-04-17
Headlines
Zentalis Pharmaceuticals Shares Rise After Leerink Upgrade
MT Newswires · 1d ago
Zentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform Rating
InvestorsHub · 2d ago
Leerink Upgrades Zentalis Pharmaceuticals to Outperform From Market Perform, Price Target is $8
MT Newswires · 2d ago
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 5d ago
William Blair Initiates Zentalis Pharmaceuticals at Outperform
MT Newswires · 21d ago
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire · 34d ago
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 35d ago
Zentalis Pharmaceuticals Insider Bought Shares Worth $15,172,500, According to a Recent SEC Filing
MT Newswires · 48d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.